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Sary The human CCNDJ/PRADI gene, located in the 1q13 chromosomal region, encodes a cyclin D
protein with potential oncogenic capacity and is involved in several human malignancies. The amplification
and expression status of CCNDI was investigated in a series of oesophageal tumours. CCNDI is amplified in
54% and overexpressed in 63% of the tumours of the squamous cell type.
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Qesophageal cancer is a frequent and deadly disease linked to
environmental factors and resulting from multiple genetic
abnormalities variously identified in the malignant cells.
Alterations of oncogenes as well as of tumour-suppressor
genes (Evans, 1993) have been observed in oesophageal
tumours (Huang et al., 1992; Jankowski et al., 1992). A
frequent mechanism of alteration is the amplification of an
oncogene locus, resulting in the existence of a high number
of copies of a key gene and the overproduction of its
messenger RNA and protein product (for review see Brison,
1993). In oesophageal cancer, amplification of several
oncogenes has been reported (for review see Yoshida et al.,
1993). Thus, MYC, ERBBI, encoding the epidermal growth
factor (EGF) receptor and potential oncogenes from the
11q13 chromosomal region can be found amplified in a high
proportion of cases (Hollstein et al., 1988; Lu et al., 1988;
Tsuda et al., 1989; Kitagawa et al., 1991; Wagata et al., 1991;
Jiang et al., 1992; Mori et al., 1992).
The 1lq13 chromosomal region, which is amplified in a
number of carcinomas (for reviews see Lammie and Peters,
1991; Gaudray et al., 1992; Brison, 1993), reafranged in
B-cell (Withers et al., 1991; Williams et al., 1993) and
parathyroid tumours (Motokura and Arnold, 1993) and
altered in multiple endocrine neoplasia type 1 (Bale et al.,
1991; Janson et al., 1991), contains several growth regulator
genes. Among these, the CCNDI gene (also caled PRADI or
CYCDJ, and representing the coding unit of the BCL1 locus)
encodes a molecule of the cyclin D family (for reviews see
Matsushime et al., 1991; Motokura et al., 1991; Xiong et al.,
1991; Motokura and Arnold, 1993), which is thought to play
a key role in the amplification (Lammie et al., 1991). How-
ever, amplification of the 11q13 region appears to result
from, or to generate, complex genomic processes. Thus, in
addition to CCNDI/PRADI, potential unidentified
oncogenes of three other 1lq13 subregions, either slightly
centromeric or telomeric of the cyclin gene (Szepetowski et
al., 1991, 1992; Brookes et al., 1993; Karlseder et al., 1994),
are susPected to be selected in some of the amplification
units. They are close to the DI1S97, EMS) (Schuuring et al.,
1992) and GARP (Ollendorff et al., 1994) loci. Fmally,
another poorly understood characteristic of the 11q13
amplification, only established so far in breast tumours, is its
frequent association with an amplification of the 8pl2
chromosomal region (Tbeillet et al., 1993).
The role of the FGF3 and FGF4 genes, encoding growth
factors of the fibroblast growth factor family and lalised
slightly telomeric of CCNDI (Hagemeijer et al., 1991;
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Brookes et al., 1993), is no longer considered important for
the development of the 1lq13 amplification units (discussed
in Lammie and Peters, 1991, and Gaudray et al., 1992) but
the initial observations of 11q13 amplification in oesophageal
carcinomas were done with probes for the FGF genes FGF3/
INT2 and FGF4/HST. Based on their amplification, a high
incidence of alteration of the 11ql3 region was observed in
oesophageal cancer (Tsuda et al., 1989; Kitagawa et al., 1991;
Wagata et al., 1991). The same incidence was later found
with a CCNDl/PRADI probe (Jiang et al., 1992). In two cell
lines with 11q13 amplification, it was possible to observe that
the CCNDI amplification, but not the FGF4 amplification,
was associated with a high level of expression (Jiang et al.,
1992). No such correlation was possible with primary
tumours using Northern blot hybridization but a recent study
reports the altered expression of the CCND1 protein in
1lq13-amplified oesophageal tumours (Jiang et al., 1993).
We have looked for amplification of CCNDI/PRADI in a
panel of oesophageal carcinomas. To assess the actual
involvement of the cyclin Dl gene in the amplification pro-
cess, we have compared its expression with its number of
copies using Northern and Southern blot hybridisations.
Adding strength to the hypothesis viewing CCNDI and a
main target of 1lq13 amplification, a strong correlation was




A panel of 55 oesophageal tumours and seven samples of
normal oesophagus was collected, prior to treatment, over
the past 2 years at the Institut Paoli-Calmettes in Marseille.
Endoscopic biopsy specimens were frozen within 15 min of
removal and were stored at - 80'C before processing.
Tumours were classified as squamous cell carcinomas
(n =44) and adenocarcinomas (n = 11). The status of p53
and EGFR proteins were determined by immunohistochemis-
try (Monges et al., 1994). The mammary carcinoma cell lines
MDA-MB.134 and MDA-MB.231, used as controls of
chromosomal 11q13 amplification (Lafage et al., 1992), were
obtaied through the Amercan Type Culture Collection and
grown according to its recommendations.
Molecularprobes
The CCNDI probe was a 1.1 kb EcoRI cDNA fragment
derived from a human placenta library using a synthetic
oligonucleotide probe corresponding to the CCNDI/PRADICCANDI in oesophageal cancers
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gene sequence (Raynaud et al., 1993) and was a gift from P.
Gaudray (Nice, France). The ETSJ probe, located at 1 1q23,
was used as control for loading in Southern blot experiments.
It was a 0.75 kb HindlII fragment from plasmid pHE5.4 (De
Taisne et al., 1984). The FGF4/HST and GARP/D1 1S833E
probes, both located at 1 1q13 telomeric of CCND1, were a
0.8 kb EcoRI-SacI genomic fragment (Adelaide et al., 1988)
and a 2.4 kb EcoRI genomic fragment (Ollendorff et al.,
1992) respectively. The Gapdh probe used in control of RNA
hybridisations was derived from a mouse clone (Galland et
al., 1990).
DNA and RNA analyses
DNA and RNA extractions were performed as follows. The
frozen tumour samples were reduced to powder using a Spex
7000 (Bioblock Scientific) in the presence of guanidinium
isothyocyanate. The powder was then heated to 50°C for
15 min. The resulting solution was centrifuged for 3 h at
50 000 r.p.m. The RNA was obtained from the pellet,
resuspended in distilled water and stored before use. The
DNA present in the supernatant was treated as previously
described (Theillet et al., 1989). Southern and Northern blot
hybridisations were performed as described by Theillet et al.
(1993). The levels of amplification were quantitatively
assessed by densitometry scanning (LKB) by comparison
with the control probe and normal tissue. Owing to a possi-
ble dilution of the tumoral component by stromal tissue
(each sample was derived from several pooled biopsies) a
cut-off value of 2-fold was chosen for amplification.
Results
Amplification ofCCND1 in human oesophageal tumours
The amplification status of the CCNDJ gene was assessed by
Southern blot analysis in a panel of 55 DNAs extracted from
oesophageal tumour samples. The results are shown in Table
I and examples of Southern blot hybridization are shown in
Figure 1. Twenty-four squamous cell tumours out of 44
(54%) showed amplification of the CCNDJ gene. Compared
with normal oesophagus, the number of gene copies was
increased between 2 and 12 times. Amplification of at least
3-fold occurred in 45% of the tumours. Amplification was
only observed in squamous carcinomas; none of the 11
adenocarcinomas exhibited amplification of CCNDJ (Table
I). A probe for the ETSJ gene, located at 11q23, was used as
a control for DNA loading. ETSJ was never amplified. Pro-
bes for the FGF4 and GARP genes (Ollendorff et al., 1994),
located at 1 1q13.3 (Adelaide et al., 1988; Hagemeijer et al.,
1991) and 11q13.5-q14 (Ollendorff et al., 1992) respectively,
were used to estimate the size and structure of the
amplification units (Figure 1). FGF4 was amplified in 11
cases out of 42 tested (26%). All cases showed amplification
of CCNDJ. GARP was amplified in 10 cases out of 42
(23.7%). In three of these cases, CCNDJ was not amplified.
Thus, there does not seem to exist fundamental qualitative
differences between lq13 amplifications in oesophageal and
Table I Amplification and overexpression of CCNDJ in human
oesophageal tumours
Tumours Amplification Overexpression A + EP
Squamous cell 24"/44 (54%) 24b/38 (63%) 22b
carcinomas
Adenocarcinomas 0/11 3/7 0
Normal oesophagus 0/7 0/5
Normal stomach 0/1 0/1
aAmplified and overexpressed. bTwo non-amplified tumours
(including 4523 shown in Figure 2) expressed CCND1 at a significant
level, and all amplified tumours overexpressed CCNDJ but two
amplified tumours could not be tested for expression (see details in
Table II).
breast cancers since co-amplification of FGF4 with CCNDJ
and independent amplification of GARP are observed (Karl-
seder et al., 1994) but the overall frequency of amplification
is higher.
Expression ofCCND1 in JJqJ3-amplified tumours
Whether the amplification of CCNDJ contributed to an
elevated expression was determined by comparison of RNA
expression with DNA amplification. We analysed the expres-
sion ofthe CCNDJ/PRADJ gene by Northern blot hybridisa-
tion of total RNAs extracted from 38 oesophageal tumours
in which both RNA and DNA could be analysed. Examples
of hybridisation are shown in Figure 2. The CCNDJ gene
was expressed as a 4.5 kb transcript. In the vast majority of
tumours without CCNDJ amplification (16/38), absence or
very low levels of expression were observed. Rare tumours,
however, showed a significant level of expression in the
absence of DNA amplification. In tumours presenting
amplification of the gene, CCNDJ expression was always
observed (24/38). The results are summarised in Tables I and
II.
Thus, in the normal oesophagus, the level of expression of
CCNDJ is either low (and barely detectable by Northern blot
analysis) or totally absent. Under pathological conditions,













Figure I Amplification of CCNDJ (located in the 1 lql3
chromosomal region) in human oesophageal tumours. Selected
DNA extracted from normal oesophagus (4339), oesophageal
squamous cell carcinoma samples and the breast carcinoma cell
line MDA-MB.134 (known to be amplified for genes of the 1 1q13
chromosomal region) were analysed by Southern blot hybridisa-
tion with CCNDJ, GARP (1 q13.5-q14) and ETSI (1 q23) pro-
bes. MDA-MB.134 and tumours 4497, 4858 and 5482 are
amplified for CCND1 (respectively 16, 2, 12 and 10 times). The
size of the bands is indicated at the left.
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Correlations with clinical andpathologicalparameters
Statistical analysis of the correlations between DNA
amplification and expression of CCNDI and clinical and
pathological parameters was performed on the panel of
oesophageal tumours. The results are summarised in Table
III. There was no obvious strong statistical correlation
between amplification, or expression, and any of the clinical
or biological parameters tested. There was no significant
association between CCNDI amplification (not shown) or
expression (Figure 3) and long-term survival (>24months).
Di~
The involvement of cyclin genes in human cancer has
recently been shown by several authors. The human cyclin
DI gene, CCDNIJPRADI, is thought to be the key gene in
the llq13 amplification observed in several types of human
cancers, as well as the long-sought BCLI oncogene (Hunter
and Pines, 1991; Motokura and Arnold, 1993). This is based
on several observations, in particular: (i) the localisation of
CCNDI in the major core of the amplified region (Karlseder
et al., 1994); (ii) a good correlation between expression and
amplification of CCNDI in tumours with an 1IqI3-amplified
region (Lammie et al., 1991); (iii) the consistent expression of
CCNDI in lymphomas with a t(I 1;14) translocation (Rosen-
berg et al., 1991; Withers et al., 1991); and (iv) the capacity
for CCNDI to be activated by tumoral rearrangements (re-
viewed in Motokura and Arnold, 1993). Furthermore, cycin
D2 and cycin E genes have been found to be amplified in
some human tumours (Buckley et al., 1993; Keyomarsi and
Pardee, 1993; Leach et al., 1993), and cyclin A can be
activated by provirus insertion in liver cancer (Wang et al.,
1990). Finally, even in the absence of amplification or trans-
Table n Comparative status of CCNDI amplification and
expression in 38 squamous cell carcnomas of the oesophagus
RNA expression Normal copy munber Amplified Total
Absence or low level 14 0 14
of expression
Expression 2 22 24
P<0.0001
Total 16 22 38
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location, various cyclin genes are overexpressed in a number
of tumours (Buckley et al., 1993; Keyomarsi and Pardee,
1993). The present report strengthens these observations. It
illustrates the possible involvement of CCNDI in squamous
cell carcinomas of the oesophagus. The incidence of amplifi-
cation and overexpression of CCNDI in this type of tumour
is high, between 45 and 54% depending on the threshold
retained for a bona fide amplification. This was expected
since it had ahready been observed that amplification of the
chromosomal region where CCNDI is located is especially
frequent in this type of cancer (Tsuda et al., 1989; Kitagawa
et al., 1991; Wagata et al., 1991). The proportion of
oesophageal tumours amplified for probes of the 1 1q13
region varies from 24% (Mori et al., 1992) to 52% (Tsuda et
al., 1989). The lowest incidence, found with an FGF3 probe,
is close to what we observed using FGF4 as a probe.
Mori et al. (1992) observed an association between
CCNDI amplification and we were unable to confirm this,
although the trend in our data is in a similar direction. At
any rate, although almost two-thirds of the squamous cell
carcinomas overexpress CCNDJ, any effect on the survival of
the patients is seen only after 12 months. Whether this
reflects the initial presence of involved lymph nodes or a
enhanced aggression of the carcinoma cells themselves re-
mains unclear at the present time.
Table m Correlation between CCNDI amplification and
prognostic parameters
Number of Number of


























































Figwe 2 Expression of CCNDI in human oesophageal tumours.
Ten micrograms of total RNA extracted from oesophageal car-
cinomas and two breast carcinoma cell lines was analysed by
Northern blot hybridisation (see Materials and methods) with a
CCNDI probe. A transcript of 4.5 kb was observed in some
tumour samples, including the two cell lines used as controls. The
Gapdh probe was used as a control. Black squares indicate that
the CCNDI gene is amplified in the corresponding tumour. All
tumour samples are from squamous cell carcinomas with the
exception of the adenocarcinoma sample 4%9, shown for com-
parison.
P= 0.4
Fugwe 3 Outcome of 38 patients with squamous cell carcinoma
of the oesophagus. The percentage overall survival is plotted
against time (in months). The difference between the survival of
patients with no detectable CCNDI expression (- - -) (by North-
ern blot analysis, see text) and that of patients with CCNDI
expression (-) (n = 24) does not reach statistical significance
(P = 0.4).
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The exact role of CCNDI should be discussed with respect
to the general complexity of the amplification process.
Amplified units can be large and can contain several
categories of genes. In addition to amplified but not over-
expressed 'silent passenger' genes and 'unwanted passengers',
which may have a negative effect on cell proliferation or on
the maintenance of the amplification and which are
eliminated, at least one pathologically relevant oncogene is
assumed to be present in an amplification unit. It corre-
sponds to the selected key 'driver' gene. In certain cases more
than one gene may be selected to create independent ampli-
cons within the same large region (Szepetowski et al., 1992;
Karlseder et al., 1994). CCNDI seems to be a key gene of the
1 1q13 amplification, and the data reported here, showing a
good correlation between amplification and expression,
strengthen this hypothesis. However, another category of
genes is the 'opportunistic passenger' genes. They are present
in the amplification unit but are not primarily selected and
responsible for the amplification. They become deregulated
and are overexpressed as a consequence of the elevated gene
copies number. CCNDI may also belong to this category,
although evidence is mounting that it actually represents a
key oncogene (see Motokura and Arnold, for a review).
In the cases with overexpression without increased gene
copy number, it is possible that the method of Southern
blotting used is not sensitive enough. This question could be
solved by using other methods, such as fluorescence in situ
hybridisation on chromosomes (Kallioniemi et al., 1992).
Alternatively, in the adenocarcinomas, it may result from a
mechanism of regulation which is intrinsically different from
the squamous subtype.
Cyclins and other components of the cell cycle, together
with regulators of genome integrity and cell survival (Hunter,
1993; Lanfrancone et al., 1994), represent 'cancer genes'
which may be as relevant to tumour development as the
so-called classical oncogenes. The analysis of their involve-
ment in human cancer is of primary importance. Thus, the
possible role of other cyclins and cell cycle components in
oesophageal tumours should continue to be analysed. The
association with possible amplification of other chromosomal
regions should also be investigated.
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